reports
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Wim Lewi
- Michiel Declercq
IBA Ready to Act (inium 225)
Earlier this week, IBA's joint venture PanTera secured € 93m in an oversubscribed Series A funding round, making it the largest in Belgian life science history. The post money valuation of € 280m implies a valuation of IBA's stake of € 88m or € 2.9ps, or comfortably above the previous book value of € 0.6ps. Incorporating this into our model, we increased our TP from € 16.0 to € 18.0 per share on Wednesday and reiterated our Buy rating. In this note, we take a closer look at the strong growth dri...
- ING Helpdesk
- Michiel Declercq
IBA Pantera gets € 280m valuation after largest Series A in Belgian LS...
This morning, IBA announced that Pantera secured € 93m in an oversubscribed series A round (the largest in Belgian life science history), valuing Pantera at € 280m post money valuation. Additionally, IBA and SFPIM will convert € 7.2m in convertible loans, while € 33.8m in debt has also been secured, bringing the total amount raised to € 134m. Following the transaction, IBA's will hold a 31.3% stake in Pantera, compared to 47.8% previously. The funds will be used primarily to support the construc...
- Guy Sips
- Michiel Declercq
- Sharad Kumar S.P
IBA’s joint venture PanTera secures EUR 93 million in oversubscribed S...
IBA’s joint venture PanTera secures EUR 93 million in oversubscribed Series A round to accelerate global actinium-225 production Louvain-la-Neuve, Belgium, September 11, 2024 – IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, is pleased to share the below press release from its joint venture PanTera, which is focussed on the production of actinium-225, a novel radioisotope used in a new class of targeted treatments for cancer. The Series A financing values PanTera at about EUR 280 million post money. Prior to the funding round, IBA had a 47.8% sharehold...
PanTera, la joint-venture d’IBA, obtient 93 millions d'euros lors d'un...
PanTera, la joint-venture d’IBA, obtient 93 millions d'euros lors d'une levée de fonds de série A sursouscrite pour accélérer la production mondiale d'actinium-225 Louvain-La-Neuve, Belgique, le 11 septembre 2024 - IBA (Ion Beam Applications S.A.), le leader mondial de la technologie d’accélération de particules, partage aujourd’hui le communiqué de presse ci-dessous concernant sa joint-venture PanTera qui a pour objectif d’assurer la production à grande échelle d'actinium-225, un radioisotope novateur utilisé dans une nouvelle classe de traitements ciblés contre le cancer. La levée de fon...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List Update September 2024 –Cofinimmo & Kinepolis in;...
In this September update of our Dynamic Top Pick List we make 4 changes. •We include Cofinimmo in our Dynamic Top Pick List after our recent upgrade from Accumulate to Buy. We expect the name to outperform in a decreasing interest rate environment given its relatively high leverage and cheap valuation. We also believe the risk of a dilutive equity raise eased when the FY24 capex decreased from € 320m to € 250m. The management stays disciplined in its capex program and continues to focus on asse...
BEKB BEKAERT SA
ABN ABN AMRO BANK NV DEPOSITARY RECEIPTS
FAGR FAGRON SA
EVS EVS BROADCAST EQUIPMENT SA
XIOR XIOR STUDENT HOUSING N.V.
SOLB SOLVAY SA
COFB COFINIMMO SA
DIE D'IETEREN SA
SOF SOFINA SA
VAN VAN DE VELDE S.A.
IBAB ION BEAM APPLICATIONS SA
ACKB ACKERMANS & VAN HAAREN NV
CPINV CARE PROPERTY INVEST SA
KIN KINEPOLIS GROUP NV
TINC TINC COMM. VA
FUR FUGRO NV
SYENS SYENSQO
- ING Helpdesk
- Guy Sips
- Hilde Van Boxstael
- Kristof Samoy
- Michiel Declercq
- Wim Hoste
- Wim Lewi
IBA Reports Half Year 2024 Results
IBA Reports Half Year 2024 Results GROUP REVENUES UP 21.9% ACCELERATED BACKLOG CONVERSION IN PROTON THERAPY AND OTHER ACCELERATORS STRONG GROSS MARGIN IMPROVEMENT AND BREAKEVEN REBIT Louvain-la-Neuve, Belgium, 29 August 2024 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the first half of 2024. (EUR 000)H1 2024H1 2023VarianceVariance %Total Revenues206 452169 41837 03421.9% Proton Therapy107 72495 08212 64213.3% Other Accelerators70 07841 35428 72469.5% Dosimetry28 64932 982-4 333-13...
IBA publie ses résultats du premier semestre 2024
IBA publie ses résultats du premier semestre 2024 REVENUS DU GROUPE EN HAUSSE DE 21,9% ACCELERATION DE LA CONVERSION DU CARNET DE COMMANDES EN PROTONTHÉRAPIE ET AUTRES ACCELERATEURS FORTE AMELIORATION DE LA MARGE BRUTE ET REBIT À L’EQUILIBRE Louvain-La-Neuve, Belgique, jeudi 29 août 2024 - IBA (Ion Beam Applications S.A.), le leader mondial de la technologie d’accélération de particules, annonce ce jour ses résultats consolidés pour le premier semestre 2024. (EUR 000)S1 2024S1 2023VariationVariation %Total Ventes et Prestations206 452169 41837 03421,9%Protonthérapie 107 72495 082...
- ING Helpdesk
- Guy Sips
- Michiel Declercq
- Guy Sips
Greenyard Continued growth in both segments; 1Q24/25 LfL sales y/y +4....
In 1Q24/25, Greenyard saw continued growth and this in both segments. Greenyard's 1Q LfL net sales increased 4.4% to € 1.34bn mainly driven by higher volumes (+2.8%), increased service sales (+1.0%) and only a slight increase in prices of 0.6% despite challenging weather conditions across Europe. Our model (Accumulate, € 9.5 Target Price) takes into account Greenyard's ambitions of reaching € 5.4bn sales and between € 200m and € 210m Adj. EBITDA in FY25/26.
IBA secures deal with the University of Pennsylvania Health System for...
IBA secures deal with the University of Pennsylvania Health System for two Proteus®ONE proton therapy solutions Agreement further strengthens the long-term relationship between IBA and the University of Pennsylvania Louvain-La-Neuve, Belgium, August 27, 2024 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a Memorandum of Understanding with the University of Pennsylvania Health System for the installation of two Proteus®ONE1 c...
IBA conclut un accord avec University of Pennsylvania Health System po...
IBA conclut un accord avec University of Pennsylvania Health System pour deux solutions de protonthérapie Proteus®ONE Un accord dans la continuité du partenariat à long terme entre IBA et University of Pennsylvania Louvain-la-Neuve, Belgique, le 27 août 2024 - IBA (Ion Beam Applications S.A., EURONEXT) le leader mondial des technologies d’accélération de particules et le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, annonce aujourd'hui avoir signé un Protocole d'Accord avec University of Pennsylvania Health System pour l'installation de deux solut...
- ING Helpdesk
Benelux Morning Notes
ASR: 1H small beat, KNAB add-on to Solvency 2 higher. Avantium: Down to the wire. Flow Traders: Pump up the volume. Greenyard: 1Q24/25 preview. Kendrion: Navigating difficult end markets. Montea: Solid results with no surprises, guidance reiterated. NEPI Rockcastle: Guidance raised, M&A opportunities on the radar. Tessenderlo: 1H24 Adj. EBITDA miss of 5%, lower FY guidance
- Michiel Declercq
IBA Model update & 1H24 preview: 2024 likely to be another transition ...
Ahead of the 1H24 results on 29 August, we have revised our estimates to the downside. Similar to last year, we expect 2024 to be a transition year for PT margins, driven by ongoing investments in IT and R&D, and the conversion of older, lower margin contracts (including Spain). In addition, the conversion of the Spanish contract could weigh on FCF in 2024 and 2025, with a reversal from 2026 onwards. Nevertheless, we keep our long-term estimates broadly unchanged, driven by the continued momentu...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.